This document discusses using data intensive science to build better disease models in a collaborative manner. It notes that current disease models often assume pathways are well understood enough to infer therapies, but reality is more complex with overlapping pathways. The document proposes a "data intensive" approach using large datasets, interoperable IT, open information systems, and hosting evolving computational models. This could help build better disease maps by facilitating identification of causal genes and evolutionary weak spots through probabilistic network models. The document advocates creating an "information commons" to advance such collaborative modeling beyond current incentives.
Bert Reijmerink (Genalice) - Hoe technologie bijdraagt aan een betere behande...AlmereDataCapital
Presentatie van Bert Reijmerink (Genalice) - 'Hoe technologie bijdraagt aan een betere behandeling van kankerpatiënten' tijdens het Big Data Analytics seminar 14 juni in Almere
Cell based assays presentation v3_03_2012Pete Shuster
Update presentation on "increasing returns in drug discovery by harnessing the power of cells". Includes images/data/pubs of differentiating human sensory and dopaminergic neurons from hNP1 neural progenitors + osteoblasts and chondrocytes from human mesenchymal stem cells. Our platforms are ideal for high throughput screening and other drug discovery processes.
A talk on high-throughput RNai and compound screening data analysis given at Finnish Institute for Molecular medicine (FIMM) March 13, 2008, 12.30—17.30.
A significant amount of time could be saved by cutting out the unnecessary steps from traditional cloning and moving into gene synthesis. Gene synthesis has become a costeffective, time- and resource-saving method for obtaining nearly any desired DNA construct with 100% accuracy. It outperforms conventional molecular biology techniques in terms of time and cost, while providing equivalent or better expression performance, and construct stability and quality. GeneArt® gene synthesis tools gobeyond traditional synthesis and enable expression optimization and maximum performance. Watch this webinar with audio at: http://owl.li/jppYn
Bert Reijmerink (Genalice) - Hoe technologie bijdraagt aan een betere behande...AlmereDataCapital
Presentatie van Bert Reijmerink (Genalice) - 'Hoe technologie bijdraagt aan een betere behandeling van kankerpatiënten' tijdens het Big Data Analytics seminar 14 juni in Almere
Cell based assays presentation v3_03_2012Pete Shuster
Update presentation on "increasing returns in drug discovery by harnessing the power of cells". Includes images/data/pubs of differentiating human sensory and dopaminergic neurons from hNP1 neural progenitors + osteoblasts and chondrocytes from human mesenchymal stem cells. Our platforms are ideal for high throughput screening and other drug discovery processes.
A talk on high-throughput RNai and compound screening data analysis given at Finnish Institute for Molecular medicine (FIMM) March 13, 2008, 12.30—17.30.
A significant amount of time could be saved by cutting out the unnecessary steps from traditional cloning and moving into gene synthesis. Gene synthesis has become a costeffective, time- and resource-saving method for obtaining nearly any desired DNA construct with 100% accuracy. It outperforms conventional molecular biology techniques in terms of time and cost, while providing equivalent or better expression performance, and construct stability and quality. GeneArt® gene synthesis tools gobeyond traditional synthesis and enable expression optimization and maximum performance. Watch this webinar with audio at: http://owl.li/jppYn
Biotechnology Industry has changed a lot during last decade , which means moving ahead from traditional ways to more advanced technological developments
2012 Biotechnology Industry is not the same as it was in 2001
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Friend UCSF 2012-07-27
1. Why not use data intensive science to build
better models of diseases together?
– beyond current rewards
Stephen
H
Friend
MD
PhD
Sage
Bionetworks
(non-‐profit)
July
27,
2012
UCSF
2.
3. So
what
is
the
problem?
Most
approved
therapies
were
assumed
to
be
monotherapies
for
diseases
represen4ng
homogenous
popula4ons
Our
exis4ng
disease
models
o9en
assume
pathway
knowledge
sufficient
to
infer
correct
therapies
8. “Data Intensive” Science- Fourth Scientific Paradigm
Equipment capable of generating
massive amounts of data
IT Interoperability
Open Information System
Host evolving computational models
in a “Compute Space”
9.
10. WHY
NOT
USE
“DATA
INTENSIVE”
SCIENCE
TO
BUILD
BETTER
DISEASE
MAPS?
11. what will it take to understand disease?
DNA
RNA
PROTEIN
(dark
maVer)
MOVING
BEYOND
ALTERED
COMPONENT
LISTS
13. Preliminary Probabalistic Models- Rosetta /Schadt
Networks facilitate direct
identification of genes that are
causal for disease
Evolutionarily tolerated weak spots
Gene symbol Gene name Variance of OFPM Mouse Source
explained by gene model
expression*
Zfp90 Zinc finger protein 90 68% tg Constructed using BAC transgenics
Gas7 Growth arrest specific 7 68% tg Constructed using BAC transgenics
Gpx3 Glutathione peroxidase 3 61% tg Provided by Prof. Oleg
Mirochnitchenko (University of
Medicine and Dentistry at New
Jersey, NJ) [12]
Lactb Lactamase beta 52% tg Constructed using BAC transgenics
Me1 Malic enzyme 1 52% ko Naturally occurring KO
Gyk Glycerol kinase 46% ko Provided by Dr. Katrina Dipple
(UCLA) [13]
Lpl Lipoprotein lipase 46% ko Provided by Dr. Ira Goldberg
(Columbia University, NY) [11]
C3ar1 Complement component 46% ko Purchased from Deltagen, CA
3a receptor 1
Tgfbr2 Transforming growth 39% ko Purchased from Deltagen, CA
Nat Genet (2005) 205:370 factor beta receptor 2
17. “Data Intensive” Science- Fourth Scientific Paradigm
Score Card for Medical Sciences
Equipment capable of generating
massive amounts of data A-
IT Interoperability D
Open Information System D-
Host evolving computational models
in a “Compute Space F
18. We still consider much clinical research as if we were
hunter gathers - not sharing
.
26. Sage Mission
Sage Bionetworks is a non-profit organization with a vision to
create a commons where integrative bionetworks are evolved by
contributor scientists with a shared vision to accelerate the
elimination of human disease
Building Disease Maps Data Repository
Commons Pilots Discovery Platform
Sagebase.org
29. Products/Approaches
Technology Platform
Governance
Impactful Models Better Models of
Disease:
INFORMATION
COMMONS
Challenges
30. IT
Cons4tuencies
Individual
Pa4ents
Technology
PlaHorm
Biotech
Governance
ImpacHul
Models
BeVer
Models
Pa4ent
of
Disease:
Founda4ons
INFORMATION
COMMONS
Pharma
Challenges
Joint
Pa4ent/
Scien4st
Academic
Communi4es
Consor4a
31. Ongoing
Sage
Bionetworks
Ini4a4ves
IT
Individual
Pharma
EU
Pa4ents
Roche PARTICIPATION
RNDP/FA/MEL
Takeda
Technology
PlaHorm
Communi2es
engaging
COMMONS
PLATFORM
Governance
WPP
ImpacHul
Models
Pa4ent
BeVer
Models
of
Founda4ons
Biotech
Disease:
INFORMATION
COMMONS
Common
Mind/
BrCA/Challenges
Mt.
Sinai
Neuro
Cell
Line
Challenges
Challenge
TCGA/Challenge
Joint
Pa4ent/
SB/Gates
Academic
Scien4st
Discovery
Consor4a
ClearScience
Communi4es
Sage CCSB Network
32. IT
Cons4tuencies
Individual
Pa4ents
Technology
PlaHorm
Biotech
Governance
ImpacHul
Models
BeVer
Models
Pa4ent
of
Disease:
Founda4ons
INFORMATION
COMMONS
Pharma
Challenges
Joint
Pa4ent/
Scien4st
Academic
Communi4es
Consor4a
33. Impactful Models
Breast Cancer: Co-expression Networks
A) Miller 159 samples B) Christos 189 samples
NKI: N Engl J Med. 2002 Dec 19;347(25):1999.
Wang: Lancet. 2005 Feb 19-25;365(9460):671.
Miller: Breast Cancer Res. 2005;7(6):R953.
Christos: J Natl Cancer Inst. 2006 15;98(4):262.
C) NKI 295 samples
E) Super modules
Cell
cycle
Pre-mRNA
ECM
D) Wang 286 samples Blood vessel
Immune
response
33
Zhang B et al., Towards a global picture of breast cancer (manuscript).
34. CHRIS
GAITERI-‐ALZHEIMER’S
What
is
this?
Bayesian
networks
enriched
in
inflammaon
genes
correlated
with
disease
severity
in
pre-‐frontal
cortex
of
250
Alzheimer’s
paents.
What
does
it
mean?
Inflammaon
in
AD
is
an
interacve
mul-‐pathway
system.
More
broadly,
network
structure
organizes
complex
disease
effects
into
coherent
sub-‐systems
and
can
priorize
key
genes.
Are
you
joking?
Gene
validaon
shows
novel
key
drivers
increase
Abeta
uptake
and
decrease
neurite
length
through
an
ROS
burst.
(highly
relevant
to
AD
pathology)
35. IMPACTFUL
MODELS
A
mul-‐ssue
immune-‐driven
theory
of
weight
loss
Hypothalamus
Lep4n
signaling
FaNy
acids
Macrophage/
inflamma4on
Liver
Adipose
M1
macrophage
Phagocytosis-‐
Phagocytosis-‐
induced
lipolysis
induced
lipolysis
36. IT
Cons4tuencies
Individual
Pa4ents
Technology
PlaHorm
Biotech
Governance
ImpacHul
Models
BeVer
Models
Pa4ent
of
Disease:
Founda4ons
INFORMATION
COMMONS
Pharma
Challenges
Joint
Pa4ent/
Scien4st
Academic
Communi4es
Consor4a
37. Two approaches to building common
scientific and technical knowledge
Every code change versioned
Every issue tracked
Text summary of the completed project Every project the starting point for new work
Assembled after the fact All evolving and accessible in real time
Social Coding
38. Synapse is GitHub for Biomedical Data
Every code change versioned
Every issue tracked
Data and code versioned Every project the starting point for new work
Analysis history captured in real time All evolving and accessible in real time
Work anywhere, and share the results with anyone Social Coding
Social Science
43. Data Analysis with Synapse
Run Any Tool
On Any Platform
Record in Synapse
Share with Anyone
44. • Automated
workflows
for
curaon,
QC,
and
sharing
of
1%/2* 53,'6%(* !7"(%,2/"* large-‐scale
datasets.
-./#"++0%(* (3&4"#*
• All
of
TCGA,
GEO,
and
user-‐submiVed
data
processed
with
standard
normalizaon
methods.
1%/2* 53,'6%(* !7"(%,2/"* • Searchable
TCGA
data:
-./#"++0%(* (3&4"#* • 23
cancers
• 11
data
plahorms
• Standardized
meta-‐data
ontologies
-./#"++0%(* -./#"++0%(*
!7"(%,2/"* !7"(%,2/"*
1%/2* 1%/2*
(3&4"#* (3&4"#*
53,'6%(* 53,'6%(*
!#"80)69"*&%8":*
;"("#'6%(*
!"#$%#&'()"*
'++"++&"(,*
45. 1%/2* 53,'6%(* !7"(%,2/"* • Comparison
of
many
modeling
approaches
applied
-./#"++0%(* (3&4"#*
to
the
same
data.
• Models
transparently
shared
and
reusable
through
-./#"++0%(*
1%/2* 53,'6%(* !7"(%,2/"* Synapse.
(3&4"#*
• Displayed
is
comparison
of
6
modeling
approaches
to
predict
sensivity
to
130
drugs.
• Extending
pipeline
to
evaluate
predicon
of
-./#"++0%(* -./#"++0%(*
!7"(%,2/"* !7"(%,2/"* TCGA
phenotypes.
1%/2* 1%/2*
(3&4"#* (3&4"#* • Hosng
of
collaborave
compeons
to
compare
53,'6%(* 53,'6%(* models
from
many
groups.
1--'&2-3$4567$
!#"80)69"*&%8":*
*&+%,-./0$
;"("#'6%(*
!"#$%#&'()"*
'++"++&"(,*
!"#$%&'()$
47. IT
Cons4tuencies
Individual
Pa4ents
Technology
PlaHorm
Biotech
Governance
ImpacHul
Models
BeVer
Models
Pa4ent
of
Disease:
Founda4ons
INFORMATION
COMMONS
Pharma
Challenges
Joint
Pa4ent/
Scien4st
Academic
Communi4es
Consor4a
48. Clinical Trial Comparator Arm
Partnership (CTCAP)
Description: Collate, Annotate, Curate and Host Clinical Trial Data
with Genomic Information from the Comparator Arms of Industry and
Foundation Sponsored Clinical Trials: Building a Site for Sharing
Data and Models to evolve better Disease Maps.
Public-Private Partnership of leading pharmaceutical companies,
clinical trial groups and researchers.
Neutral Conveners: Sage Bionetworks and Genetic Alliance
[nonprofits].
Initiative to share existing trial data (molecular and clinical) from
non-proprietary comparator and placebo arms to create powerful
new tool for drug development.
Started Sept 2010
49. Shared clinical/genomic data sharing and analysis will
maximize clinical impact and enable discovery
• Graphic
of
curated
to
qced
to
models
50. Arch2POCM
Restructuring
the
Precompeve
Space
for
Drug
Discovery
How
to
potenally
De-‐Risk
High-‐Risk
Therapeuc
Areas
53. How can we accelerate the pace of scientific discovery?
2008
2009
2010
2011
Ways to move beyond
“traditional” collaborations?
Intra-lab vs Inter-lab
Communication
Pfizer CTI/ Industrial PPPs
Academic Unions
55. sage federation:
model of biological age
Faster Aging
Predicted
Age
(liver
expression)
Slower Aging
Clinical Association
- Gender
- BMI
- Disease
Age Differential Genotype Association
Gene Pathway Expression
Chronological
Age
(years)
56. Reproducible
science==shareable
science
Sweave: combines programmatic analysis with narrative
Dynamic generation of statistical reports
using literate data analysis
Sweave.Friedrich Leisch. Sweave: Dynamic generation of statistical reports
using literate data analysis. In Wolfgang Härdle and Bernd Rönz,editors, Compstat 2002 –
Proceedings in Computational Statistics,pages 575-580.
Physica Verlag, Heidelberg, 2002. ISBN 3-7908-1517-9
62. IT
Cons4tuencies
Individual
Pa4ents
Technology
PlaHorm
Biotech
Governance
ImpacHul
Models
BeVer
Models
Pa4ent
of
Disease:
Founda4ons
INFORMATION
COMMONS
Pharma
Challenges
Joint
Pa4ent/
Scien4st
Academic
Communi4es
Consor4a
63. What
is the problem?
Our current models of disease biology are primitive and
limit doctor’s understanding and ability to treat patients
Current incentives reward those who
silo information and work in closed
systems
64. The Solution: Competitions to crowd-source
research in biology and other fields
Why competitions?
• Objective assessments
• Acceleration of progress
• Transparency
• Reproducibility
• Extensible, reusable models
Competitions in biomedical research
• CASP (protein structure)
• Fold it / EteRNA (protein / RNA structure)
• CAGI (genome annotation)
• Assemblethon / alignathon (genome assembly / alignment)
• SBV Improver (industrial methodology benchmarking)
• DREAM (co-organizer of Sage/DREAM competition)
Generic competition platforms
• Kaggle, Innocentive, MLComp
65. The Sage/DREAM breast cancer prognosis
challenge
Goal: Challenge to assess the accuracy of computational models designed to
predict breast cancer survival using patient clinical and genomic data
Why this is unique:
This Sage/DREAM Challenge is a pre-collated cohort: 2000 breast cancer samples
from the Metabric cohort
Accessible to all: A cloud-based common compute architecture is being made
available by Google to support the computational models needed to develop and test
challenge models
New Rigor:
• Contestants will evaluate their models on a validation data set composed of newly generated
data (provided by Dr. Anne-Lise Borreson Dale)
• Contestants must demonstrate their models can be reproduced by others
New incentives: leaderboard to energize participants, Science Translational Medicine
publication for winning team
Breast cancer patients, funders and researchers can track this Challenge on BRIDGE,
an open source online community being built by Sage and Ashoka Changemakers and
affiliated with this Challenge
66. Sage/DREAM Challenge: Details and Timing
Phase
1: July thru end-Sep 2012 Phase
2:
Oct 1 thru Nov 12, 2012
Training data: 2,000 breast cancer
samples from METABRIC cohort Evaluation of models in novel
dataset.
• Gene expression
• Copy number Validation data: ~500 fresh frozen
• Clinical covariates tumors from Norway group with:
• 10 year survival • Clinical covariates
Supporting data: Other Sage-curated • 10 year survival
breast cancer datasets
• >1,000 samples from GEO Gene expression and copy number
data to be generated for model
• ~800 samples from TCGA evaluation
• ~500 additional samples from • Sent to Cancer Research UK to
Norway group generate data at same facility as
• Curated and available on METABRIC
Synapse, Sage’s compute • Models built on training data
platform evaluated on newly generated
data
Data released in phases on Synapse
from now through end-September
Winners announced at November
12 DREAM conference
Will evaluate accuracy of models built
on METABRIC data to predict survival
in:
• Held out samples from
METABRIC
• Other datasets
67. METABRIC
cohort:
1%/2* 53,'6%(* !7"(%,2/"* 997
breast
cancer
samples
-./#"++0%(* (3&4"#*
Clinical
covariates
1%/2* 53,'6%(* !7"(%,2/"*
-./#"++0%(* (3&4"#* Gene
expression
(Illumina
HT12v3)
Copy
number
(Affy
SNP
6.0)
-./#"++0%(* -./#"++0%(*
!7"(%,2/"* !7"(%,2/"*
1%/2* 1%/2*
(3&4"#* (3&4"#*
53,'6%(* 53,'6%(*
10
year
survival
!#"80)69"*&%8":*
;"("#'6%(*
!"#$%#&'()"*
'++"++&"(,*
Loaded
through
Synapse
R
client
as
Bioconductor
objects.
68. 1%/2* 53,'6%(* !7"(%,2/"*
-./#"++0%(* (3&4"#*
1%/2* 53,'6%(* !7"(%,2/"*
-./#"++0%(* (3&4"#*
-./#"++0%(* -./#"++0%(*
!7"(%,2/"* !7"(%,2/"*
1%/2* 1%/2* Custom
models
implement
train()
and
(3&4"#* (3&4"#* predict()
API.
53,'6%(* 53,'6%(*
!#"80)69"*&%8":*
;"("#'6%(*
!"#$%#&'()"*
'++"++&"(,*
Implementa)on
of
simple
clinical-‐only
survival
model
used
as
baseline
predictor.
70. Summary
hVps://synapse.sagebase.org/
-‐
BCCOverview:0
Transparency,
Valida4on
in
novel
reproducibility
-./#"++0%(*
1%/2*
(3&4"#* 53,'6%(* !7"(%,2/"*
dataset
1%/2* 53,'6%(* !7"(%,2/"*
-./#"++0%(* (3&4"#*
-./#"++0%(* -./#"++0%(*
!7"(%,2/"* !7"(%,2/"*
1%/2* 1%/2*
(3&4"#* (3&4"#*
53,'6%(* 53,'6%(*
!#"80)69"*&%8":*
;"("#'6%(*
!"#$%#&'()"*
'++"++&"(,*
Publica4on
in
Science
Dona4on
of
Google-‐
Transla4onal
Medicine
scale
compute
space.
For
the
goal
of
promo4ng
democra4za4on
of
medicine…
Registra4on
star4ng
NOW…
sign
up
at:
synapse.sagebase.org
71.
72.
73. SUMMARY
These
new
data
intensive
models
of
disease
will
be
strikingly
powerful
They
will
not
arise
within
the
current
academic/industrial
loop
They
will
be
harder
and
more
expensive
than
we
can
accept
Cizenss
as
donors
of
data
insights
and
funds
will
be
crical
For
these
benefits
to
be
realized
-‐
must
become
affordable
therefore
we
willl
need:
Compute
spaces
A
Commons
New
ways
of
being
rewarded
More
eyeballs
working
without
being
paid
More
willingness
to
share
ll
aoer
Clinical
Proof
of
Concept
74. Alignments between the UCSF Strategic Plan
and the matchstick pilots for the Information
Commons being pursued by Sage Bionetworks
• Invest in infrastructure that enables UCSF to excel in basic,
clinical and population science- SYNAPSE as a compute space
-links with Michael Wiener/ OneMind
• Build a Bioinformatics initiative across all school by
June
2014- Impactful Models / Challenges with Laura Esserman/
LauraVant’Veer
• Enhance existing data repositories and mining tools by June
2012 - Sage collaborations with Alex Pico, Geoff Manley
• Develop infrastructure to support new team-based,
interdisciplinary learning models- PLC (The Federation?)
• Accelerate translation of groundbreaking science into
therapies Arch2POCM